The increase in breast cancer rates among younger patients is occurring as the incidence of other early-onset cancers — including colorectal, gastric, kidney and liver cancer — is also on the rise, though cancer among patients under 50 is still relatively rare overall, Dr. Partridge said.

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic breast cancer who had progressed on multiple line of therapy.

The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with unresectable or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

Cancer diagnoses are shifting from older to younger adults and from men to women, according to a report released Thursday by the American Cancer Society.